GLP-1 receptor agonists ‘reduce kidney failure and deaths’: meta-analysis
Commenting on the study, Associate Professor Neale Cohen said it was an important step forward for the drug class.
GLP-1 receptor agonists offer significant renal protection as well as cardiovascular benefits, a meta-analysis shows.
Australian-led research has found that patients taking the drugs have a lower risk of kidney failure, heart failure and all-cause death, regardless of their diabetes status.
Published in The Lancet Diabetes and Endocrinology, the meta-analysis included 11 large-scale clinical trials involving 67,769 participants with type 2 diabetes and 17,604 with obesity or cardiovascular disease but no diabetes history.
Compared with placebo, GLP-1 receptor agonists (RAs) reduced the risk of kidney failure by 16% and slowed kidney function decline by 22%.
